Cancers: well-controlled viremia predicts hepatocellular carcinoma prognosis in patients with chronic viral hepatitis treated with sorafenib

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death in the world and the second largest cause of cancer-related death in
Taiwan.

In recent years, with sequential therapies emerging after sorafenib, including new effective targeted therapies such as regorafenib, cabozantinib, or ramucirumab, as well as immunotherapies such as nivolumab or pembrolizumab, the OS of patients receiving a clue rafenib treatment is expected to improve
further.

Objective: This study attempts to elucidate the efficacy
of sorafenib and antiviral therapy in patients with HCC who cannot be removed in the real world with HBV or hepatitis C virus infection.

Methods: Between January 2018 and January 2021, 256 patients with
unresectable HCC who received one-lead rafenib treatment were evaluated.

Results: We enrolled 116 (65.

Table 1 Sorafenib response to treatment in patients with HCC

Table 2 Treatment-related adverse events (TRAE)
in patients with HBV-HCC and hepatitis C virus-HCC.

Figure 1 (A) Progression-free survival in patients with HBV-HCC and hepatitis C virus-HCC
.

Figure 2 (i
).

Figure 3 (i
).

Table 3 Factors
associated with overall survival in patients with sorafenib in univariate and multivariate analyses.

Conclusions: In real life, HBV or hepatitis C virus infection has no effect on the prognosis of HCC patients receiving sorafenib therapy; However, viremia is controlled does have an impact
.

Source: Kuo YH, Huang TH, Wang JH,et al.